IL7R+ CD8 T cells have been shown to be a stem-like tumor-reactive CD8 T cell population as was shown in head and neck cancer (Eberhardt et al., 2021) and is related to a better clinical outcome upon immunotherapy (33, 34). This evidence concerns the gene CD8A and head and neck cancer.